IP Library › Granted Patent US 12,269,840
Granted Patent B2
US 12,269,840 · App. 17/299,087 · Granted Apr 8, 2025

Process for the preparation of a cyclic dinucleotide

Inventors: Michael Anthony Schmidt (Cranbury, NJ); Bin Zheng (Kendall Park, NJ); Benjamin M. Cohen (Cranford, NJ); Amanda J. Rogers (Asbury, NJ); Changxia Yuan (Warren, NJ); Jason J. Zhu (East Brunswick, NJ); Chao Hang (Monmouth Junction, NJ); Daniel S. Treitler (Cranford, NJ); Adam Joseph Freitag (Hopewell, NJ); Geoffrey Eugene Purdum (Freehold, NJ); Miao Yu (Malvern, PA); Melda Sezen Edmonds (Princeton, NJ); Siwei Guo (Vacaville, CA)
Assignee: BRISTOL-MYERS SQUIBB COMPANY
C07H21/00C07H1/00C07H19/16C07H19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,840
App. No.
17/299,087
Granted
Apr 8, 2025
Kind
B2
Abstract

The invention generally relates to an improved processes for the preparation of a cyclic dinucleotide which is useful as a STING agonist of the following formula (I), involving the use of compounds A and B.

Claims (29)

1. A process for the preparation of Compound I having the formula

comprising the steps of

a) reacting Compound 1 with TBSCl and Et 3 N

to afford Compound 2;

b) reacting Compound 2 with a phosphorus (V) compound consisting of Compound A to afford Compound 3

c) reacting Compound 3 and Compound 9

to afford Compound 4;

d) reacting Compound 4 in a solvent, and then adding a base, followed by the addition of a phosphorus (V) compound consisting of Compound B

 to afford Compound 5 having the formula

e) selectively deprotecting Compound 5 to afford Compound 6 having the formula

f) the Compound 6 is cyclized in a suitable solvent under basic conditions to afford Compound 7 having the formula

g) the Compound 7 is subsequently mixed in a suitable base, stirred and concentrated to afford Compound 8 having the formula

and h) the Compound 8 is subsequently deprotected to afford Compound I.

2. The process according to claim 1 , wherein step b) further comprises a base selected from imidazole, DBU, diisopropylethylamine, triazole, tetrazole, metal alkoxide bases, lithium diisopropylamide, sodium bis(trimethysiliyl)amide or other amide bases.

3. The process according to claim 2 , wherein the base is imidazole.

4. The process according to claim 1 , wherein step c) further comprises a solvent selected from THF, MeCN or DMF.

5. The process according to claim 4 , wherein the solvent is THF.

6. The process according to claim 1 , wherein step c) further comprises a base selected from lithium diisopropylamide, sodium bis(trimethysiliyl)amide, other amide bases, potassium t-butoxide, DBU or other alkoxide bases.

7. The process according to claim 6 , wherein the base in step c) is sodium tert-pentoxide or sodium t-amylate.

8. The process according to claim 1 , wherein the solvent in step d) is THF, 2-MeTHF, MeCN or DMF.

9. The process according to claim 8 , wherein the solvent in step d) is 2-MeTHF.

10. The process according to claim 1 , wherein the base in step d) is imidazole, DBU, triazole, tetrazole, diisopropylethylamine or other t-butoxides.

11. The process according to claim 10 , wherein the base in step d) is imidazole.

12. The process according to claim 1 , wherein the solvent in step f) is THF, MeCN, NMP or DMF or mixtures thereof.

13. The process according to claim 12 , wherein the solvent in step f) is a mixture of THF and NMP.

14. The process according to claim 1 , wherein the base in step f) is lithium diisopropylamide, potassium bis(trimethylsilyl)amide, other amide bases, potassium t-butoxide, DBU, other alkoxide bases, NaHMDS or other alkylsilylamines.

15. The process according to claim 14 , wherein the base in step f) is lithium t-butoxide.

16. The process according to claim 1 , wherein the base in step g) is methylamine, ammonium or other alkylamine bases.

17. The process according to claim 16 , wherein the base in step g) is methylamine.

Continuity (2)
Provisional Application 62775094 · Dec 4, 2018
Related Publication 20220064205A1 · Mar 3, 2022
References Cited (9)
US 10604542B2 · Glick et al. · 2020 [cited by applicant]
WO 17123669A1 · 2017 [cited by applicant]
WO WO2017123669A1 · 2017 [cited by examiner]
WO 19200273A1 · 2019 [cited by applicant]
Knouse et al. Unlocking P(V): Reagents for chiral phosphorothioate synthesis. Science, 361(6408), 1234-1238. https://doi.org/10.1126/science.aau3369 (Year: 2018). [cited by examiner]
Monticelli et al. Recent advancements on the use of 2-methyltetrahydrofuran in organometallic chemistry. Monatshefte Für Chemie—Chemical Monthly, 148(1), 37-48. https://doi.org/10.1007/s00706-016-1879-3 (Year: 2016). [cited by examiner]
Richaud, A., Barba-Behrens, N., & Méndez, F. Chemical reactivity of the imidazole: a semblance of pyridine and pyrrole? Organic Letters, 13(5), 972-975. https://doi.org/10.1021/ol103011h (Year: 2011). [cited by examiner]
Kojima, Naoshi, et al., “Synthesis of ribonucleic guanidine: replacement of the negative phosphodiester linkages of RNA with positive guanidinium linkages”, Tetrahedron, 2002, vol. 58, pp. 867-879. [cited by applicant]
Mellal, D., et al. “Synthesis and biological evaluation of non-isomerizable analogues of Ala-tRNAAla” Org. Biomol. Chem. vol. 11(36) pp. 6161-6169 (2013). [cited by applicant]